Home / Guides / Tirzepatide maintenance dose
Reached your goal? Here’s what’s next.
Tirzepatide maintenance dose: what to expect once you reach your goal
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
A tirzepatide maintenance dose is 5 mg, 10 mg or 15 mg once a week, per Zepbound’s label (read November 1, 2026); your provider picks yours. At NexLife, compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, at every dose.
$139/mo on 12 months, every dosePrice Match Guarantee†
- Maintenance doses: 5, 10 or 15 mg, once a week
- 2.5 mg is a starting dose, not a maintenance dose
- Your provider decides whether to hold, lower or stop
$139/mo on a 12-month plan, all-inclusive, same price at every dose
Or $169/mo month to month
Staying on or stepping down? Your price stays the same at every dose
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Lowest monthly price | $139 | $1,668 |
| 6-month | $149 | $1,788 |
| 3-month | $159 | $1,908 |
| Month to month | $169 | $2,028 |
Month to month costs $360 more over 12 months than the 12-month plan. Plans renew until you cancel. Longer plans bill the way you choose at checkout.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
At a glance
Tirzepatide maintenance dose at a glance
The short answers, from Zepbound’s label and two trials. Each one is explained below.
| Question | Answer |
|---|---|
| What are the maintenance doses? | 5 mg, 10 mg or 15 mg once a week, on Zepbound’s label. Your provider picks yours. |
| Is 2.5 mg a maintenance dose? | No. It’s only for starting treatment. |
| Can 5 mg keep weight off? | Most of it, on average. In SURMOUNT-MAINTAIN, weight rose 7.0% in a year after stepping down to 5 mg, and 15.2% on placebo. |
| What if you stop? | Much of the weight came back, on average: up 14.0% in the year after switching to placebo, in SURMOUNT-4. |
| Every other week, or microdosing? | Neither is in the label, and neither was tested in these trials. |
| What does NexLife charge? | $139 a month on the 12-month plan, or $169 month to month, at every dose. |
Both trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied, and it isn’t FDA-approved. NexLife’s prices checked November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- The maintenance dose on Zepbound’s label is 5 mg, 10 mg or 15 mg once a week; your provider picks yours.
- 2.5 mg is only a starting dose. For sleep apnea, the maintenance doses are 10 or 15 mg.
- Staying on held weight steady. In SURMOUNT-MAINTAIN, weight rose 7.0% after stepping down to 5 mg, and 15.2% on placebo.
- Stopping brought weight back: up 14.0% in the year after switching to placebo, in SURMOUNT-4. Both trials studied Zepbound, not compounded tirzepatide.
- Stepping down to 5 mg costs less on Zepbound at LillyDirect: $399 per 4 weeks (checked November 1, 2026).
- At NexLife, every dose costs the same: $139 a month on the 12-month plan, or $169 month to month.
The label
What is the tirzepatide maintenance dose on Zepbound’s label?
Zepbound’s label (revised August 2026) lists three maintenance doses: 5 mg, 10 mg and 15 mg, once a week. Your provider picks one by how you respond and how you tolerate it. The 2.5 mg you started on is only a starting dose, not one to stay on. For sleep apnea, the maintenance doses are 10 or 15 mg.
“The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
| Weekly dose | What the Zepbound label says | A maintenance dose? |
|---|---|---|
| 2.5 mgweeks 1 to 4 | The starting dose, for 4 weeks. It’s for starting treatment, not for maintenance. | No |
| 5 mg | The lowest maintenance dose. It’s for weight, not for sleep apnea. | Yes, for weight |
| 7.5 mg | A step up, after at least 4 weeks at 5 mg. | No, a step |
| 10 mg | A maintenance dose, for weight and for sleep apnea. | Yes |
| 12.5 mg | A step up, after at least 4 weeks at 10 mg. | No, a step |
| 15 mgthe maximum | A maintenance dose, and the most the label allows. | Yes |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026) and Lilly’s dosing page for healthcare providers, both read November 1, 2026. Every dose is taken once a week.
How your provider chooses. The label says to weigh how well you respond and how you tolerate the dose. If a maintenance dose doesn’t agree with you, it says to consider a lower one.
“If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
On compounded tirzepatide, your prescription sets your dose and your schedule. How many units that is depends on your vial’s strength: see our tirzepatide dosage chart.
Stalled before your goal? That’s a plateau, which is a different question: see tirzepatide plateau.
Dose and vial math
How many units is a maintenance dose?
It depends on your vial’s strength. At an example strength of 25 mg per mL, the three maintenance doses are 20, 40 and 60 units on a U-100 syringe.
| Weekly dose | Volume at 25 mg/mL (example) | Units on a U-100 syringe |
|---|---|---|
| 5 mgmaintenance dose | 0.2 mL | 20 units |
| 7.5 mga step, not a maintenance dose | 0.3 mL | 30 units |
| 10 mgmaintenance dose | 0.4 mL | 40 units |
| 12.5 mga step, not a maintenance dose | 0.5 mL | 50 units |
| 15 mgmaintenance dose, the maximum | 0.6 mL | 60 units |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. So 10 mg ÷ 25 mg/mL = 0.4 mL, or 40 units. At the same strength, stepping down from 10 mg to 5 mg halves what you draw: 40 units becomes 20.
25 mg/mL is an example only. It’s the strength of Zepbound’s 15 mg multi-dose vial on its February 2026 FDA label. Your vial’s label decides the strength, and your prescription sets your dose. Zepbound’s own doses are set volumes: 0.5 mL from a single-dose pen or vial, or 0.6 mL from a multi-dose vial or KwikPen, which holds four doses.
Check before you draw. The FDA has reported dosing errors with compounded semaglutide, and says mix-ups between milliliters, milligrams and units may have contributed. If a number doesn’t match your prescription, ask your provider before you inject; at NexLife, call or text
The 2026 trial
Can a lower dose keep weight off? What SURMOUNT-MAINTAIN found
Most of it, on average. In SURMOUNT-MAINTAIN (The Lancet, 2026), people who had lost weight on 10 or 15 mg held steady for another year on that dose. Weight rose 7.0% after stepping down to 5 mg, and 15.2% on placebo. The trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
60 weeks at the full dose
441 adults took tirzepatide at the highest dose they tolerated, 10 or 15 mg.
Three groups for a year
378 who had lost at least 5% were split at random into three groups for 52 weeks. They stayed on that dose (140 people), stepped down to 5 mg (144) or switched to placebo (94).
A safety net
Everyone had diet and activity counseling. From week 84, anyone who regained more than half their loss could restart tirzepatide.
| Group, after 60 weeks at 10 or 15 mg | Week 112, vs starting weight | Weight change in the maintenance year | Kept 80% or more of their loss* | Restarted tirzepatide (rescue) |
|---|---|---|---|---|
| Stayed on their dose140 people | −21.9% | −0.2% (held steady) | 77.5%, about 3 in 4 | 8% (11 of 138) |
| Stepped down to 5 mg144 people | −16.6% | +7.0% | 42.4%, about 2 in 5 | 25% (35 of 142) |
| Switched to placebo94 people | −9.9% | +15.2% | 10.4%, about 1 in 10 | 67% (60 of 90) |
Swipe the table sideways to see every column.
SURMOUNT-MAINTAIN (Horn et al., The Lancet, 2026): the trial’s main results, counting everyone randomized. *Among people whose weight had leveled off by week 60. This trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
What it means. On average, the full dose held the weight off. 5 mg held most of it, and placebo much less. Results on 5 mg varied from person to person, the authors note.
Fewer stomach side effects on 5 mg. In the maintenance year, nausea, vomiting or diarrhea affected 14% of people on the full dose, 7% on 5 mg and 3% on placebo.
Seen 22.4% and 17.0% elsewhere? Those figures, in Lilly’s press release, estimate what would have happened if everyone had stayed on their assigned treatment. On that basis, the three groups were 22.4%, 17.0% and 10.1% below their starting weight.
Stopping
What happens when you stop tirzepatide? What SURMOUNT-4 found
Much of the weight came back. In SURMOUNT-4 (JAMA, 2024), people switched to placebo after 36 weeks on Zepbound saw their weight rise 14.0% over the next year, on average, despite diet and activity counseling. Those who stayed on it lost another 5.5%. The trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
| Group, after 36 weeks on Zepbound | Weight change, week 36 to week 88 |
|---|---|
| Switched to placebo335 people | +14.0% |
| Kept taking Zepbound335 people | −5.5% |
Swipe the table sideways to see every column.
Study 4 (SURMOUNT-4) in the Zepbound prescribing information, and the trial’s paper in JAMA (2024). 783 people started Zepbound, stepping up to 10 or 15 mg. After 36 weeks, the 670 who went on had lost 20.9% on average, and were randomly assigned to keep taking it or switch to placebo for 52 weeks. This trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
The same pattern in SURMOUNT-MAINTAIN. On placebo, weight rose 15.2% in a year, and 2 in 3 people regained enough to restart tirzepatide.
Neither trial tested stopping after a few months. Both switched people to placebo only after 36 or 60 weeks of treatment.
An average isn’t a forecast for you. Some people keep more weight off than others. Your provider can help you plan, whatever you decide.
Not studied
Microdosing or every-other-week tirzepatide: what’s not studied?
Going below 5 mg, dosing every other week and microdosing. The Zepbound label (revised August 2026) lists none of them for maintenance, and neither SURMOUNT-MAINTAIN nor SURMOUNT-4 tested them. Without a trial, no one knows how well they hold weight off. If you want a lower dose, ask your provider about 5 mg.
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
| Maintenance plan | The Zepbound label | The trials on this page |
|---|---|---|
| Stay at 10 or 15 mg | A maintenance dose | Held weight off, on average, in both trials |
| Step down to 5 mg | A maintenance dose, for weight | Held most of it, on average (SURMOUNT-MAINTAIN) |
| Go down to 2.5 mg | A starting dose only | Not tested for maintenance |
| Every other week | Not in the label: every dose is weekly | Not tested |
| Microdosing | Not in the label | Not studied |
| Stop | No stopping schedule | Weight came back, on average, in both trials |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026), SURMOUNT-MAINTAIN and SURMOUNT-4. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Why “not studied” matters. Without a trial, there’s no good evidence on how well a lower dose or a longer gap holds your weight, or how it feels.
Want a lower dose? 5 mg once a week is the label’s lowest maintenance dose, and the one SURMOUNT-MAINTAIN tested. If side effects are the reason, tell your provider: the label says to consider a lower maintenance dose when one isn’t tolerated. More on tirzepatide side effects.
Cost
What does tirzepatide maintenance cost per year?
It depends on whether the price follows your dose. At LillyDirect, Zepbound at 5 mg is $399 per 4 weeks, or $5,187 a year (checked November 1, 2026). A flat price costs the same at 5 mg as at 15 mg, so stepping down changes nothing there.
| Program | How it’s priced | Per month | A year |
|---|---|---|---|
| NexLife, 12-month plancompounded | One price at every dose | $139 | $1,668 |
| NexLife, month to monthcompounded | One price at every dose | $169 | $2,028 |
| Zepbound at LillyDirect, 5 mgbrand-name, self-pay | By dose | $399 per 4 weeks | $5,187 |
| Zepbound at LillyDirect, 10 or 15 mgbrand-name; $449 with a refill within 45 days, or $699 if not | By dose | $449 per 4 weeks | $5,837 |
Swipe the table sideways to see every column.
Prices as each company lists them: LillyDirect checked November 1, 2026, NexLife November 1, 2026. NexLife’s prices include the provider and shipping; LillyDirect’s is for the medication alone. A year is our math: 13 four-week supplies for Zepbound, 12 months for NexLife. Zepbound’s $449 needs a refill within 45 days; otherwise it’s $699 at 10 to 15 mg. Compounded tirzepatide isn’t FDA-approved; Zepbound is. If insurance covers Zepbound for you, it may cost less.
NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works
Staying at 10 or 15 mg, or stepping down to 5 mg? At a flat price, it costs the same: $1,668 a year on NexLife’s 12-month plan either way. At LillyDirect, stepping down saves $650 a year.
Where a price set by dose wins. If your maintenance dose falls in a program’s lowest tier, you can pay less there than at a flat price, ours included. Before you prepay anywhere, ask for the price at your maintenance dose in writing: a dose tier or a dose step can change it. Our Price Match Guarantee† matches regular month-to-month prices, not prepaid multi-month programs.
Where a flat price wins. It doesn’t change if your provider moves your dose up or down, now or later. Who offers one: flat-rate tirzepatide.
Every dose, priced: tirzepatide cost by dose. The lowest prices we track: most affordable compounded tirzepatide.
With your provider
How do you stop taking tirzepatide?
With a plan you make with your provider. The Zepbound label (revised August 2026) sets no taper or stopping schedule. Stepping down to 5 mg is the middle path SURMOUNT-MAINTAIN tested. Talk through why you want to stop and what you’ll watch, so the plan fits you.
Say why you want to stop
Cost, side effects or reaching your goal each lead to a different plan. Pregnant? The label says to stop Zepbound once a pregnancy is recognized, so tell your provider right away.
Ask about the middle path
Stepping down to 5 mg is the option SURMOUNT-MAINTAIN tested with Zepbound. Your provider decides whether it fits you.
Agree on what you’ll watch
Settle with your provider how you’ll track your weight, and when to check back in.
Know how restarting works
After a long break, your provider may restart you at a lower dose. Here’s how that works: restarting tirzepatide after a break.
Keep the habits either way. In both trials, people had diet and activity counseling throughout. On placebo, much of the weight still came back, on average. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Do you have to stay on it forever? Not necessarily. But Zepbound is approved to reduce excess weight and keep it off long term, and the SURMOUNT-MAINTAIN authors concluded that long-term treatment is often needed.
At NexLife
Maintenance with NexLife
A licensed provider follows your dose, and your price doesn’t change with it. Here’s how it works.
Your provider follows your dose
A licensed provider reviews how you’re doing and decides whether to keep your dose, lower it or stop.
One price at every dose
$139 a month on the 12-month plan, or $169 month to month. Stepping down to 5 mg, or back up, doesn’t change it.
Help when you need it
A nutrition plan and a 1:1 coaching call are included. Real people answer 24/7 at
(949) 818-8000 .Each refill ships free
Expedited shipping; most orders ship within 1 to 2 business days.
Paying with HSA or FSA? Both work, and NexLife provides a letter of medical necessity. Affirm, Klarna and Afterpay are at checkout too.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Tirzepatide maintenance: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What is the maintenance dose of tirzepatide?
Zepbound’s label lists 5 mg, 10 mg and 15 mg of tirzepatide once a week as maintenance doses; your provider picks yours. 2.5 mg is only a starting dose, and 15 mg is the most the label allows. For sleep apnea, the maintenance doses are 10 or 15 mg.
Can I go down to 5 mg after I reach my goal?
Possibly: 5 mg is one of the label’s maintenance doses for weight, and your provider decides. In SURMOUNT-MAINTAIN, people stepped down to 5 mg after 60 weeks on 10 or 15 mg. Their weight rose 7.0% over the next year, on average, while it held steady on the full dose. This trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Can I take tirzepatide every other week?
Not by the label: every Zepbound dose is taken once a week, and no trial on this page tested every-other-week dosing. If you want a lower dose, 5 mg once a week is the label’s lowest maintenance dose, and the one SURMOUNT-MAINTAIN tested. Your provider decides what fits you.
Can I microdose tirzepatide for maintenance?
Microdosing isn’t studied: the Zepbound label has no microdose, and no trial on this page tested one. The label’s lowest dose, 2.5 mg, is only for starting treatment. If you want a lower dose, ask your provider about 5 mg, the label’s lowest maintenance dose.
What happens if I stop tirzepatide after reaching my goal?
On average, much of the weight comes back. In SURMOUNT-4, weight rose 14.0% in the year after people switched to placebo, while those who stayed on Zepbound lost another 5.5%. In SURMOUNT-MAINTAIN, weight rose 15.2% in a year on placebo. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
What happens if I stop tirzepatide after 3 months?
No trial on this page tested that: SURMOUNT-4 and SURMOUNT-MAINTAIN switched people to placebo only after 36 or 60 weeks. In both, much of the lost weight came back within a year, on average. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Do I have to take tirzepatide forever?
Not necessarily, though Zepbound is approved to reduce excess weight and keep it off long term. In trials, much of the weight came back after people stopped; the SURMOUNT-MAINTAIN authors concluded long-term treatment is often needed. The trials studied FDA-approved Zepbound, not compounded tirzepatide. Your provider can help you weigh staying on, stepping down or stopping.
How much does maintenance cost at NexLife?
Compounded tirzepatide at NexLife is $139 a month on the 12-month plan, or $169 month to month, at every dose. That’s $1,668 or $2,028 a year, at 5 mg or 15 mg, with no membership fee. The 12-month plan costs $360 a year less than paying month to month.
Does a lower maintenance dose cause fewer side effects?
It did in SURMOUNT-MAINTAIN: in the maintenance year, nausea, vomiting or diarrhea affected 14% of people on the full dose, 7% on 5 mg and 3% on placebo. If side effects are why you want a lower dose, tell your provider. The trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
How does a provider choose your tirzepatide maintenance dose?
By how well you respond and how you tolerate the dose, as Zepbound’s label says. Stepping down to 5 mg is the option SURMOUNT-MAINTAIN tested, and your provider decides whether it fits you. On compounded tirzepatide, your prescription sets your dose and your schedule.
Do diet and exercise still matter on a maintenance dose?
Yes. Keep the habits either way: in SURMOUNT-MAINTAIN and SURMOUNT-4, people had diet and activity counseling throughout, yet on placebo much of the weight still came back, on average. At NexLife, a nutrition plan and a 1:1 coaching call are included.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Labels and trials read November 1, 2026. Other programs’ prices checked November 1, 2026.
- How we checked. The maintenance doses come from the Zepbound prescribing information (revised August 2026) and Lilly’s dosing page for healthcare providers. The SURMOUNT-MAINTAIN results come from the trial’s paper in The Lancet, checked against Lilly’s press release of May 12, 2026; the SURMOUNT-4 results come from the label and the trial’s paper in JAMA. We read them all on November 1, 2026. NexLife’s prices come from our pricing page (November 1, 2026); other programs’ prices are as our guides list them, checked November 1, 2026. We don’t give a maintenance dose: your provider decides.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Staying on or stepping down? Your price stays the same.
Start online in about 3 minutes, and a licensed provider decides your dose. $139 a month on the 12-month plan, or $169 month to month, at every dose.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 1, 2026.
- Lilly: Zepbound dosing, for healthcare providers. Read November 1, 2026.
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet 2026; 407: 2305–18. Read October 22, 2026.
- Eli Lilly: Foundayo and lower-dose Zepbound helped people maintain weight loss (press release, May 12, 2026). Read November 1, 2026.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 2024; 331: 38–48. Read October 22, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 1, 2026.
- NexLife: pricing, every plan. Checked November 1, 2026.
- Eli Lilly and Company, via Drugs@FDA. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information, revised 02/2026. Read November 2, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Read November 2, 2026.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Read November 2, 2026.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Read November 2, 2026.
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. Read November 2, 2026.
- U.S. Food and Drug Administration. Human Drug Compounding Laws. Read November 2, 2026.
- U.S. Food and Drug Administration. Locate a State-Licensed Online Pharmacy. Read November 2, 2026.